Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Pulmonary Pharmacology & Therapeutics
|
April 7, 2021
The pharmacology of the prostaglandin D<sub>2</sub> receptor 2 (DP<sub>2</sub>) receptor antagonist, fevipiprant
Chris Brightling, Swarupa Kulkarni, Bart N Lambrecht, et al.
Drug Research
|
March 8, 2021
Xinting Wang, Christian Bartels, Swarupa Kulkarni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 26, 2021
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator
H Markus Weiss, Thomas Langenickel, Meredith Cain, et al.
Cancer Chemotherapy and Pharmacology
|
September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Pulmonary Pharmacology & Therapeutics
|
November 20, 2021
Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3
Swarupa Kulkarni, Birk Poller, Anton Drollmann, et al.
The AAPS Journal
|
February 14, 2023
Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039
Alexandros Kourentas, Monika Gajewska, Wen Lin, et al.
Clinical Drug Investigation
|
February 4, 2017
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
Sara Armani, Lillian Ting, Nicholas Sauter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 15, 2012
Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity
Jeffrey M Axten, Jesús R Medina, Charles W Blackledge, et al.
Journal of Medicinal Chemistry
|
May 24, 2021
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Darren Le Grand, Martin Gosling, Urs Baettig, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Pulmonary Pharmacology & Therapeutics
|
April 7, 2021
The pharmacology of the prostaglandin D<sub>2</sub> receptor 2 (DP<sub>2</sub>) receptor antagonist, fevipiprant
Chris Brightling, Swarupa Kulkarni, Bart N Lambrecht, et al.
Drug Research
|
March 8, 2021
Xinting Wang, Christian Bartels, Swarupa Kulkarni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 26, 2021
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator
H Markus Weiss, Thomas Langenickel, Meredith Cain, et al.
Cancer Chemotherapy and Pharmacology
|
September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Pulmonary Pharmacology & Therapeutics
|
November 20, 2021
Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3
Swarupa Kulkarni, Birk Poller, Anton Drollmann, et al.
The AAPS Journal
|
February 14, 2023
Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039
Alexandros Kourentas, Monika Gajewska, Wen Lin, et al.
Clinical Drug Investigation
|
February 4, 2017
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
Sara Armani, Lillian Ting, Nicholas Sauter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 15, 2012
Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity
Jeffrey M Axten, Jesús R Medina, Charles W Blackledge, et al.
Journal of Medicinal Chemistry
|
May 24, 2021
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Darren Le Grand, Martin Gosling, Urs Baettig, et al.
Page
of 1